Literature DB >> 18383620

Effects of lipid-lowering therapy on coronary heart disease in older patients: the SAGE study.

Michael Clearfield.   

Abstract

Entities:  

Year:  2008        PMID： 18383620

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  32 in total

1.  The failure of torcetrapib: was it the molecule or the mechanism?

Authors:  Alan R Tall; Laurent Yvan-Charvet; Nan Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02       Impact factor: 8.311

2.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.

Authors:  A Inazu; M L Brown; C B Hesler; L B Agellon; J Koizumi; K Takata; Y Maruhama; H Mabuchi; A R Tall
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

4.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

5.  Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Authors:  Jean-Claude Tardif; Jean Grégoire; Philippe L L'Allier; Reda Ibrahim; Jacques Lespérance; Therese M Heinonen; Simon Kouz; Colin Berry; Russell Basser; Marc-André Lavoie; Marie-Claude Guertin; Josep Rodés-Cabau
Journal:  JAMA       Date:  2007-03-26       Impact factor: 56.272

Review 6.  Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art.

Authors:  John R Crouse
Journal:  J Lipid Res       Date:  2006-05-16       Impact factor: 5.922

7.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.

Authors:  Allen J Taylor; Lance E Sullenberger; Hyun J Lee; Jeannie K Lee; Karen A Grace
Journal:  Circulation       Date:  2004-11-10       Impact factor: 29.690

8.  Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study.

Authors:  Anath Oren; Lydia E Vos; Cuno S P M Uiterwaal; Diederick E Grobbee; Michiel L Bots
Journal:  Arch Intern Med       Date:  2003 Aug 11-25

9.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Paul Schoenhagen; B Greg Brown; Peter Ganz; Robert A Vogel; Tim Crowe; Gail Howard; Christopher J Cooper; Bruce Brodie; Cindy L Grines; Anthony N DeMaria
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

10.  Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection.

Authors:  Steven M Kent; Allen J Taylor
Journal:  Am J Cardiol       Date:  2003-11-15       Impact factor: 2.778
View more
  1 in total

1.  A novel dietary supplement containing multiple phytochemicals and vitamins elevates hepatorenal and cardiac antioxidant enzymes in the absence of significant serum chemistry and genomic changes.

Authors:  Elida Bulku; Daniel Zinkovsky; Payal Patel; Vishal Javia; Tejas Lahoti; Inna Khodos; Sidney J Stohs; Sidhartha D Ray
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.